Perjeta (pertuzumab) / Roche 
Welcome,         Profile    Billing    Logout  
 80 Diseases   208 Trials   208 Trials   5617 News 


«12...3233343536373839404142...7172»
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Journal:  Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action. (Pubmed Central) -  Jul 8, 2021   
    This multimodal mechanism of action is found only in few of the tetravalent constructs investigated, which must target specific epitopes on HER2 in a defined geometric arrangement. The inhibitory effect of our antibody as single agent surpasses the combination of trastuzumab and pertuzumab as well as its parental mAbs in vitro and it is effective in a xenograft model.
  • ||||||||||  paclitaxel / Generic mfg.
    [VIRTUAL] In vitro microRNA expression profile alterations under HER2-targeted therapy in breast cancer () -  Jul 7, 2021 - Abstract #GSS2021GSS_6;    
    Methods This study analyzes intracellular and extracellular microRNA expression level alterations under six HER2-directed therapeutics: Trastuzumab, Per- tuzumab, T-DM1 and their combinations with paclitaxel...The miR-signature let-7a / let- 7e / miR-17 / miR-103 / miR-451 showed significant regulation patterns under paclitaxel plus trastuzumab and paclitaxel plus trastuzumab and pertuzumab in the extracellular compartment across all cell lines...Conclusion MiR-15a is a promising intracellular and therefore tissue biomarker for trastuzumab based therapies. The miR-signature let-7a / let-7e / miR- 17 / miR-103 / miR-451 is a potential biomarker tool in liquid biopsies to indicate therapy response for trastuzumab, let-7a and miR-451 for T- DM1.
  • ||||||||||  paclitaxel / Generic mfg.
    Review, Journal, BRCA Biomarker, PD(L)-1 Biomarker:  SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer. (Pubmed Central) -  Jul 6, 2021   
    An update from the DESTINY-Breast01 trial reported a median PFS of 19.4 months with trastuzumab deruxtecan in heavily pretreated patients. Finally, an analysis from the PERTAIN trial with > 6 years median follow-up showed excellent OS in patients with luminal B/HER2-positive receiving first-line trastuzumab/pertuzumab in combination with endocrine therapy suggesting that chemotherapy-free treatment is an option in highly selected patients.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical, Review, Journal:  Targeted therapy for breast cancer in older patients. (Pubmed Central) -  Jul 4, 2021   
    Most data guiding the use of targeted agents in older patients come from sub-analysis of larger trials or small retrospective cohort studies. The goal of this review is to go over the available evidence regarding the efficacy and safety of targeted agents approved for use in breast cancer (trastuzumab, lapatinib, T-DM1, pertuzumab, neratinib, palbociclib, bevacizumab, ribociclib, abemaciclib, everolimus, olaparib, talazoparib), and place their side effects into an older-specific context in order to help medical oncologists when making treatment decisions and managing older patients with breast cancer.
  • ||||||||||  Perjeta (pertuzumab) / Roche
    Journal:  Design and evaluation of scFv-RTX-A as a novel immunotoxin for breast cancer treatment: an in silico approach. (Pubmed Central) -  Jul 4, 2021   
    The scFv+RTX-A could be a non-allergenic and stable chimeric protein, and the secondary structure of its components did not alter, and this protein had a proper 3D structure that might have stable mRNA structure which could bind to HER2. Given the fact that the designed immunotoxin was a non-allergenic and stable chimeric protein and that it could bind with high affinity to HER2 receptors, we proposed that this chimeric protein could be a useful candidate for HER-2 positive BC patients.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Review, Journal:  Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies. (Pubmed Central) -  Jul 4, 2021   
    Despite these advances, brain and leptomeningeal metastases from HER2-positive breast cancer remain a significant cause of morbidity and mortality, and their optimal management remains an unmet need. This review presents an update on the current and novel treatment strategies for patients with brain metastases from HER2-positive breast cancer and discusses the open questions in the field.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Journal:  Peptide Based Imaging Agents for HER2 Imaging in Oncology. (Pubmed Central) -  Jul 3, 2021   
    HER2 specific peptides under development will help improve the diagnosis and potentially therapy options for HER2 positive breast cancer. Peptides showing specificity for HER2 could start widespread development of molecular imaging techniques for HER2 positive cancers.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Trial completion date, Trial primary completion date, Metastases:  Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast (clinicaltrials.gov) -  Jun 29, 2021   
    P1/2,  N=36, Recruiting, 
    This review summarises the state of the data and publishes the results of the survey completed by experts at the 2021 St. Gallen Breast Cancer Conference on early-stage breast cancer. Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2021 --> Jul 2022
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Clinical data, Review, Journal:  Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data. (Pubmed Central) -  Jun 25, 2021   
    In this article, we review the studies that support the use of HER2-directed monoclonal antibodies in early-stage breast cancer both in the adjuvant and neoadjuvant settings and focus on the success of dual HER2-targeted therapy achieved with the combination of trastuzumab and pertuzumab. A newer way to administer these agents, specifically the subcutaneous formulation of pertuzumab and trastuzumab with recombinant human hyaluronidase, will also be discussed.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
    Clinical, Journal, Adverse events:  Dermatological Side Effects of Targeted Antineoplastic Therapies: A Prospective Study. (Pubmed Central) -  Jun 24, 2021   
    Forty-two patients were using trastuzumab (single therapy in 29 patients and combined therapy in 13 patients), five patients were using cetuximab, three patients were using sunitinib, eight patients were using panitumumab, and six patients were using pertuzumab...In seven patients who developed acneiform side effects, systemic doxycycline was used, and in others, topical tetracycline and clindamycin were used...To treat these side effects, emollients, topical steroids, and local, systemic antibiotics are recommended. Clindamycin may be preferred as a topical treatment, and doxycycline may be preferred as a systematic treatment.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre, Perjeta (pertuzumab) / Roche
    Clinical, FDA event, Journal, HEOR, Real-world evidence:  Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval. (Pubmed Central) -  Jun 24, 2021   
    In our cohort of patients treated within a diverse healthcare network, the majority of patients with node-positive HER2-positive breast cancer received adjuvant pertuzumab following FDA approval. The use of adjuvant neratinib was less common, potentially as a result of adverse effects, prolongation of therapy, previous administration of adjuvant pertuzumab, and modest benefit.
  • ||||||||||  Perjeta (pertuzumab) / Roche
    Journal:  A liposome-based cancer vaccine for a rapid and high-titre anti-ErbB-2 antibody response. (Pubmed Central) -  Jun 22, 2021   
    Here, a liposomal system comprised of spatially separated ErbB-2 peptide, to activate B cells, and ovalbumin peptide OVA, to provide non-cognate T cell support, was used to generate antibodies against the epitope of the ErbB-2 protein targeted by Pertuzumab, a monoclonal antibody licensed for the treatment of ErbB-2 expressing cancers...Notably, antibody responses were demonstrated to induce cell death in vitro, resulting in 96% reduction in viable cells. This study, therefore, demonstrates the feasibility of this approach to generate a rapid, high-titre, isotype-switched, antibody response that specifically targets ErbB-2 overexpression on tumour cells and is capable of inducing cell death in vitro in the absence of complement or immune cells.
  • ||||||||||  Perjeta (pertuzumab) / Roche
    Journal:  Characterization and elimination of artificial non-covalent light Chain dimers in reduced CE-SDS analysis of pertuzumab. (Pubmed Central) -  Jun 22, 2021   
    Finally, a developed rCE-SDS method is presented for successful evaluation of pertuzumab purity and impurities, which is further confirmed by an alternative reduced microchip-based gel electrophoresis. In summary, the developed method provided an accurate and reliable purity evaluation and size variant profiling for batch releasing, stability testing and quality study of reduced pertuzumab samples.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
    Review, Journal, HEOR:  Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews. (Pubmed Central) -  Jun 22, 2021   
    Heterogeneous evidence from cost-effectiveness studies on the use of targeted directed agents for HER2-positive mBC across the world caution against cross-country comparisons of the value of such treatments. It also militates in favor of the production and use of cost-effectiveness analyses for local rather than global decision-making, thus ensuring that economic evaluations reflect the needs of local decision-makers and populations for which they are devised.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Preclinical, Journal, IO biomarker:  A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo. (Pubmed Central) -  Jun 22, 2021   
    It also induced tumor regression as potently as the combination of the two mAbs in nude mice bearing ovarian and gastric cancer xenografts. Our data suggest that trasintuzumab may be a promising BsAb therapeutic candidate for the treatment of HER2-overexpressing cancers.
  • ||||||||||  Herceptin (trastuzumab) / Roche, SIBP-01 (trastuzumab biosimilar) / Sinopharm, Herzuma (trastuzumab biosimilar) / Nippon Kayaku, Pfizer, Mundipharma, Celltrion, Teva
    Clinical, Clinical data, Journal, Real-world evidence:  Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer. (Pubmed Central) -  Jun 22, 2021   
    The ORR, DCR, and cardiac safety profiles did not also show significant difference efficacy outcomes between two groups. These real-world data suggest that biosimilar trastuzumab CT-P6 has similar effectiveness and cardiac safety to RTZ in HER2-positive EBC and MBC patients, when administered as part of dual HER2-targeted therapy with pertuzumab plus chemotherapy in the neoadjuvant or palliative setting.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Enrollment closed, Metastases:  PATINA: Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (clinicaltrials.gov) -  Jun 15, 2021   
    P3,  N=496, Active, not recruiting, 
    These real-world data suggest that biosimilar trastuzumab CT-P6 has similar effectiveness and cardiac safety to RTZ in HER2-positive EBC and MBC patients, when administered as part of dual HER2-targeted therapy with pertuzumab plus chemotherapy in the neoadjuvant or palliative setting. Recruiting --> Active, not recruiting
  • ||||||||||  Review, Journal:  Novel HER2-targeted therapies for HER2-positive metastatic breast cancer. (Pubmed Central) -  Jun 12, 2021   
    With the advent of monoclonal HER2-targeting antibodies (trastuzumab and pertuzumab) and antibody-drug conjugates (trastuzumab emtansine [T-DM1] and trastuzumab deruxtecan), clinical outcomes for HER2-positive breast cancer have dramatically changed, and a greater proportion of patients in the nonmetastatic setting are cured...Over the last year, there has been a dramatic shift in the current treatment paradigms for HER2-positive metastatic breast cancer, with recent U.S. Food and Drug Administration approvals of trastuzumab deruxtecan (DS-8201), neratinib, and tucatinib in combination with trastuzumab and capecitabine. The authors summarize recent phase 3 data with novel HER2-targeted therapies as well as phase 1 and 2 data with other novel HER2-targeting agents.